12.0 510(k) Summary (Page 1 of 1):

Submitter's Name: Fei Law, Quality and Regulatory Manager, U.S. Solutions

Phone: (386) 274-2811

Fax: (386) 274-2833

Contact: Fei Law

Date Prepared: 08/12/05

Trade Name: DryAC Acid Concentrate Mix for Bicarbonate Hemodialysis

Common Name: Dialysate Concentrate for Bicarbonate Hemodialysis

Classification Name: Dialysate Concentrate for Hemodialysis (Liquid or Powder)

Equivalent Predicate: DryAC Acid Concentrate Mix for Bicarbonate Dialysis
Gambro Renal Products, K011368

Device Description: Gambro DryAC is an acid concentrate mix used for the preparation of acid dialysis concentrate solutions that are used in bicarbonate hemodialysis.

Intended Use: Gambro DryAC acid concentrate mix for bicarbonate Hemodialysis is indicated for use with concentrated bicarbonate solution in 3-stream proportioning artificial kidney equipment using purified, AAMI standard water.

Predicate Device Comparison: The modified Gambro DryAC device has the same intended use, indication for use, chemical composition and ingredient concentrations as the predicate device. There are no significant technological changes.

The Gambro DryAC Acid Concentrate Mix for Bicarbonate Dialysis described in this submission is, in our opinion, substantially equivalent to the predicate device.
Ms. Fei Law  
Quality and Regulatory Manager  
U.S. Solutions  
Gambro Renal Products  
1845 Mason Avenue  
DAYTONA BEACH FL 32117  

Re: K052253  
Trade/Device Name: DryAC Acid Concentrate Mix for Bicarbonate Hemodialysis  
Regulation Number: 21 CFR §876.5820  
Regulation Name: Hemodialysis system and accessories  
Regulatory Class: II  
Product Code: KPO  
Dated: September 23, 2005  
Received: October 3, 2005  

Dear Ms. Law:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531–542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Description</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 CFR 876.xxxx</td>
<td>Gastroenterology/Renal/Urology</td>
<td>240-276-0115</td>
</tr>
<tr>
<td>21 CFR 884.xxxx</td>
<td>Obstetrics/Gynecology</td>
<td>240-276-0115</td>
</tr>
<tr>
<td>21 CFR 892.xxxx</td>
<td>Radiology</td>
<td>240-276-0120</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>240-276-0100</td>
</tr>
</tbody>
</table>

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Nancy C. Brogdon
Director, Division of Reproductive, Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known): K052253

Device Name: DryAC Acid Concentrate Mix for Bicarbonate Hemodialysis

Indications For Use:

Gambro DryAC acid concentrate mix for bicarbonate hemodialysis is indicated for use with concentrated bicarbonate solution in 3-stream proportioning artificial kidney equipment using purified, AAMI standard water.

Prescription Use X

AND/OR Over-The-Counter Use

(Please do not write below this line - continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)